Alan Watt MBA, PhD

Alan has over 30 years of experience in drug discovery and development in both the pharmaceutical and biotechnology sectors. His previous roles include serving as vice president of therapeutics at Bicycle Therapeutics, as chief operating officer and executive vice president of R&D at Trident Pharmaceuticals, and as chief executive officer of Xenovium. Alan formerly led inflammasome discovery at GlaxoSmithKline, where he established the Pattern Recognition Receptor Discovery Performance Unit within GSK’s Immuno-Inflammation Centre of Excellence for Drug Discovery (CEDD). He also previously served as head of drug metabolism and in vivo pharmacology at Merck. Alan holds a Bachelor of Science in chemistry from the University of Southampton, a Ph.D. in drug metabolism from the University of Hertfordshire and an MBA from the Open Business School. He has over 50 peer-reviewed scientific publications.